Some of the best links we picked up around the internet
By: Gorm Palmgren - Oct. 15, 2021
Top picks
With a little help from CRISPR, lizards can now grow replicate tails much more like the original one. When a lost tail grows back, a molecular signal only produced in adults inhibits the development of skeletal and nerve tissue, so the tail is composed of just cartilage. Researchers from the University of Southern California used CRISPR to knock out the Smo gene in neural stem cells, so they became unresponsive to the signal. When edited stem cells were grafted into adult animals with lost tails, they developed new tails with cartilage, skeletal and nervous tissues.
Sarepta Therapeutics has offered 6,172,840 shares of its common stock with an option to purchase up to an additional 925,926 shares. At $81.00 per share, the deal amounts to $500 million. Sarepta is working in precision genetic medicine for rare diseases, like Duchenne muscular dystrophy and limb-girdle muscular dystrophies.
Hunterian Medicine has acquired a non-exclusive license to use Inscripta's MAD7 nuclease for gene-editing programs to develop human therapeutics. MAD7 is an engineered nuclease of the Cas12a/Cpf1 family that targets TTTN PAMs.
Allogene's troubles have also affected its primary rival, CRISPR Therapeutics. Still, analysts have been split as they compare the outlook for the two companies: shares of Allogene went up while CRISPR Therapeutics tumbled. Read two analyses of the situation in BioPharma Dive and Investor's Business Daily.
Want to know more about the FDA hold-back that recently hit Allogene's allogeneic CAR-T therapy CTX110? And how it has affected the other players in the market? Then read this piece in Evaluate Vantage by Jacob Plieth.
CRISPR Therapeutics has presented positive results from its ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. CTX110 was well tolerated, and clinical data demonstrate the potential for CTX110 to produce durable remissions.
A handheld device that uses detection simultaneously by Cas12a and Cas13a in a single tube is described by Chinese researchers. As a proof-of-concept, reliable dual-gene detection of SARS-CoV-2 and African Swine fever virus (ASFV) was demonstrated, exhibiting 100% sensitivity and specificity for clinical samples.
Future Medicine brings an interview with Geoff MacKay, who talks about new gene therapies for rare diseases. MacKay is the CEO of AVROBIO, a clinical-stage lentiviral gene therapy company that treats lysosomal disorders, and a board member of Talaris Therapeutics and Satellos Bioscience.